11 To 14 Amino Acid Residues In Defined Sequence Patents (Class 530/327)
-
Patent number: 8524493Abstract: The present invention is directed to methods of detecting viable epithelial cells in a sample. The method includes isolating the sample comprising cells from a patient and culturing the cells for a time sufficient for an epithelial cell-specific marker to be released from the cells. The marker includes a substantially full-length cytokeratin. The method further includes detecting the released marker. Detection of the marker indicates the presence of disseminated epithelial cells. Methods are also directed to identifying disseminated epithelial tumor cells.Type: GrantFiled: September 4, 2007Date of Patent: September 3, 2013Assignee: Centre Hospitalier Universitaire de MontpellierInventors: Catherine Panabières, Klaus Pantel, Jean-Pierre Vendrell
-
Patent number: 8524673Abstract: A pharmaceutical formulation for a PKC modulatory peptide and a transport moiety comprising the aforementioned components and an anti-aggregant.Type: GrantFiled: April 21, 2010Date of Patent: September 3, 2013Assignee: KAI Pharmaceuticals, Inc.Inventor: Mike Tso-ping Li
-
Publication number: 20130224760Abstract: Described herein are compounds and methods useful in the detection of, e.g., Zn2+, in vitro and in vivo. The compounds include amino acids and peptides functionalized with a moiety that binds, e.g., Zn2+. The peptides may be further functionalized with a detectable moiety. The peptides may also comprise amino acid sequences known to localize extracellularly or in specific areas within a cell.Type: ApplicationFiled: January 14, 2013Publication date: August 29, 2013Applicant: Massachusetts Institute of TechnologyInventors: Robert J. Radford, Stephen J. Lippard
-
Publication number: 20130225481Abstract: The present invention relates to antimicrobial peptides, to their use as antimicrobial agents and to their use in the treatment of (infectious) diseases, in particular infectious diseases caused by Gram-positive bacteria, Gram-negative bacteria, yeast or fungi. The present invention further relates to pharmaceutical compositions and kits comprising the antimicrobial peptides and to a method of lysing bacterial, yeast or fungal cells. The antimicrobial peptides consist of one of the following general formula: Wherein X is a hydrophobic amino acid, Y is a cationic amino acid, Z is an amino acid having a free thiol or thioether group, n is 2-4 and m is 0 or 1.Type: ApplicationFiled: October 31, 2011Publication date: August 29, 2013Applicant: Agency for Science, Technology and ResearchInventors: Yi-Yan Yang, Nikken Wiradharma, Charlotte A.E. Hauser
-
Publication number: 20130225488Abstract: The present invention provides novel peptidomimetics, of formula (I), which primarily act as glucose dependent insulin secretagogues. Furthermore, it was found that these peptidomimetics showed glucagon receptor antagonistic activity, along with the GLP-1 receptor agonistic activity.Type: ApplicationFiled: September 28, 2007Publication date: August 29, 2013Inventors: Rajesh H. Bahekar, Braj Bhushan Lohray, Vidya Bhushan Lohray, Mukul R. Jain, Kaushik M. Banerjee, Pankaj Ramanbhai Patel
-
Publication number: 20130224880Abstract: The invention provides an isolated peptide comprising a crotonylation site, a Kcr-specific affinity reagent that specifically binds to the peptide, and a method for detecting protein crotonylation in a sample using the reagent.Type: ApplicationFiled: December 27, 2012Publication date: August 29, 2013Applicant: PTM Biolabs, Inc.Inventor: PTM Biolabs, Inc.
-
Patent number: 8518871Abstract: The present disclosure provides peptides and peptide compositions, which facilitate the delivery of an active agent or an active agent carrier wherein the compositions are capable of penetrating the stratum corneum (SC) and/or the cellular membranes of viable cells.Type: GrantFiled: October 5, 2011Date of Patent: August 27, 2013Assignee: The Regents of the University of CaliforniaInventors: Tracy Hsu, Samir M. Mitragotri
-
Publication number: 20130217634Abstract: The present disclosure concerns peptides able to interfere and in particular impair the inhibiting activity of MDM2/MDM4 heterodimer towards p53 and maintain the association between MDM4 and p53 so to restore the p53 oncosuppressive function in cancer cells harboring wild type p53 protein, directing its function specifically towards an apoptotic outcome.Type: ApplicationFiled: February 21, 2013Publication date: August 22, 2013Applicants: UNIVERSITA' DEGLI STUDI DI PERUGIA, CONSIGLIO NAZIONALE DELLE RICERCHEInventors: CONSIGLIO NAZIONALE DELLE RICERCHE, UNIVERSITA' DEGLI STUDI DI PERUGIA
-
Publication number: 20130217046Abstract: Provided herein are methods and materials for diagnosing an esophageal or esophageal-related disorder, or a predisposition for such disorders, in a subject. The methods center on detecting a genetic or protein esophageal marker. An esophageal marker has been identified in the PLCE1 gene and may be useful in predicting disease progression and assessing the subject's response to therapy.Type: ApplicationFiled: June 23, 2011Publication date: August 22, 2013Applicant: The Board of Trustees of the Univer. of IllinoisInventors: Wancai Yang, Li-Dong Wang
-
Publication number: 20130217858Abstract: The ?c-family cytokines, Interleukin-2 (IL-2), Interleukin-4 (IL-4), Interleukin-7 (IL-7), Interleukin-9 (IL-9), Interleukin-15 (IL-15), and Interleukin-21 (IL-21), are associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (GvHD). Thus, inhibitors of ?c-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools. The present embodiments relate to the design of peptide antagonists based on the consensus ?c-subunit binding site to inhibit ?c-cytokine activity. In several embodiments, peptide antagonists exhibit Simul-Block activity, inhibiting the activity of multiple ?c-cytokine family members.Type: ApplicationFiled: April 23, 2013Publication date: August 22, 2013Applicant: BIONIZ, LLCInventor: BIONIZ, LLC
-
Publication number: 20130216583Abstract: The invention relates to a vaccine which comprises at least one antigen and a peptide comprising a sequence R1-XZXZNXZX-R2, whereby N is a whole number between 3 and 7, preferably 5, X is a positively charged natural and/or non-natural amino acid residue, Z is an amino acid residue selected from the group consisting of L, V, I, F and/or W, and R1 and R2 are selected independently one from the other from the group consisting of —H, —NH2, —COCH3, —COH, a peptide with up to 20 amino acid residues or a peptide reactive group or a peptide linker with or without a peptide; X-R2 may also be an amide, ester or thioester of the C-terminal amino acid residue, as well as the use of said peptide for the preparation of an adjuvant for enhancing the immune response to at least one antigen.Type: ApplicationFiled: January 16, 2013Publication date: August 22, 2013Applicant: Intercell AGInventor: Intercell AG
-
Publication number: 20130217857Abstract: Peptides, mimetics and antibodies of erbB, TNF, and IgSF receptors and pharmaceutical compositions comprising the same are described. Methods of using such antibodies, peptides, and mimetics in therapeutic, prophylactic, imaging and diagnostic applications are disclosed.Type: ApplicationFiled: April 25, 2013Publication date: August 22, 2013Applicant: The Trustees of the University of PennsylvaniaInventor: The Trustees of the University of Pennsylvania
-
Publication number: 20130216567Abstract: The invention relates to a newly identified avian rotavirus D VP6 nucleotide sequence and uses thereof.Type: ApplicationFiled: March 4, 2011Publication date: August 22, 2013Applicant: Novartis AGInventor: Bernhard Roth
-
Publication number: 20130217047Abstract: The present invention relates to a method for the accurate, rapid and sensitive detection of breast or ovarian cancers from body fluid samples of a mammalian subject and related assay, kits and peptides suitable for such a method.Type: ApplicationFiled: September 23, 2011Publication date: August 22, 2013Applicant: AYANDA BIOSYSTEMS SAInventors: Solomzi Makohliso, Irmgard Irminger-Finger, Fernando Herrera
-
Patent number: 8512702Abstract: The present invention relates to novel antibodies and their use for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof. The present invention also relates to novel pharmaceutical compositions for the treatment of prostate cancer. Furthermore the present invention relates to assay systems and kits for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof.Type: GrantFiled: December 14, 2011Date of Patent: August 20, 2013Assignee: Proscan Rx Pharma Inc.Inventors: Claudio Cuello, Uri Saragovi, Pierre Du Ruisseau, Phil Gold, Nicole Bernard, Serge Moffett
-
Patent number: 8513185Abstract: Peptides are provided consisting of L- and/or D-amino acids and combinations thereof, which affect myeloid cells by action on the triggering receptors expressed on myeloid cells (TREMs), including TREM-1 and TREM-2. The peptides act on the TREM/DAP-12 signaling complex. Also provided are lipid and sugar conjugated peptides comprising L- or D-amino acids. A method is provided of designing the peptides and lipid- and/or sugar-conjugated peptides comprising L- or D-amino acids. The disclosure relates to the therapy of various myeloid cell-related disease states involving the use of these peptides and compounds. The peptides and compounds are useful in the treatment and/or prevention of a disease or condition where myeloid cells are involved or recruited. The peptides of the present invention also are useful in the production of medical devices comprising peptide matrices (for example, medical implants and implantable devices).Type: GrantFiled: October 13, 2010Date of Patent: August 20, 2013Inventor: Alexander B. Sigalov
-
Patent number: 8513388Abstract: The present invention relates to novel antibodies that bind specifically to human Notch 3 and their use in the detection and/or diagnosis of Notch 3 related diseases, such as cancer. The present invention also includes nucleic acids encoding these novel antibodies, vectors and cell lines harboring the nucleic acids, and kits comprising the antibodies for use in the detection and diagnosis.Type: GrantFiled: June 30, 2011Date of Patent: August 20, 2013Assignee: Genentech, Inc.Inventors: Kang Li, Sek Chung Fung, Zhengbin Yao
-
Patent number: 8513197Abstract: Disclosed are compositions and methods for treating Guillain-Barré syndrome (GBS) in a subject that involves neutralizing specific pathogenic anti-glycolipid antibodies in the circulation of the subject. This can involve administering to the subject a molecular mimic of a ganglioside that serves as a specific competitive inhibitor for anti-ganglioside antibodies in the circulation. Also disclosed is an animal model of GBS having anti-ganglioside antibodies in the circulation.Type: GrantFiled: July 31, 2012Date of Patent: August 20, 2013Assignee: Georgia Regents UniversityInventors: Robert Yu, Seigo Usuki
-
Publication number: 20130210709Abstract: The invention relates generally to compounds which are allosteric modulators (e.g., positive and negative allosteric modulators, and allosteric agonists) of the G protein coupled receptor for stromal derived factor 1 (SDF-I), also known as the CX-CR4 receptor. The CXCR4 receptor compounds are derived from the intracellular loops and domains of the CXCR4 receptor. The invention also relates to the use of these CXCR4 receptor compounds and pharmaceutical compositions comprising the CXCR4 receptor compounds in the treatment of diseases and conditions associated with CXCR4 modulation such as bone marrow trans-plantation, chemosensitization, cancer, metastatic disease, inflammatory diseases, HIV infection and stem cell-based regenerative medicine.Type: ApplicationFiled: November 4, 2009Publication date: August 15, 2013Inventors: Thomas J. McMurry, Athan Kuliopulos, Lidija Covic, Boris Tchernychev
-
Publication number: 20130210706Abstract: Novel peptide compounds and pharmaceutical compositions thereof are disclosed that have a formula represented by the following formula (I) wherein L1, L2, L3, Z, R1, R2, R4 and R5 are as described herein. The compounds demonstrate antimicrobial activity and may be prepared as pharmaceutical compositions and used for the prevention and treatment of a variety of conditions in mammals including humans where microbial invasion is involved. The present peptides are particularly valuable as their effect is rapid, broad in spectrum and mostly indifferent to resistance provided by standard antibiotics.Type: ApplicationFiled: August 26, 2011Publication date: August 15, 2013Inventors: Neville Robert Kallenbach, Filbert Totsingan
-
Publication number: 20130210750Abstract: The present invention provides a polypeptide TF1 for inhibiting type-2 Shiga-toxin activity, an encoding gene for the same and use thereof. The present polypeptide is named TF1 (also known as P1); its amino acid sequence is shown in Sequence 1 in the sequence list. The polypeptide P1 can be prepared into medicine for preventing and/or treating diseases caused by type-2 Shiga toxin or the pathogens which produce type-2 Shiga toxin.Type: ApplicationFiled: September 9, 2011Publication date: August 15, 2013Applicant: Institute of Microbiology and Epidemiology Academy of Military Medical SciencesInventors: Hui Wang, Tao Li, Qin Wang, Wei Tu, Xiaojun Hou
-
Publication number: 20130210749Abstract: The invention provides novel peptides and constructs. In addition the invention provides methods for carrying compounds across the cell membrane, for antagonizing or destroying X-protein of HBV, treatment and/or management of HBV infection, treatment and/or prevention of HCC, and degradation of a target protein.Type: ApplicationFiled: June 10, 2011Publication date: August 15, 2013Applicant: Auckland Uniservices LimitedInventor: Geoffrey Wayne Krissansen
-
Publication number: 20130209359Abstract: Cancers are extremely heterogeneous in terms of the frequency and types of mutations present in different malignant tumors. Thus, it is likely that uniform clinical treatment is not optimal for all patients, and that the development of individualized therapeutic regimens may be beneficial. Multiple, unique small peptides bind to cell lines derived from different colon adenocarcinomas. Within two hours of contact, the colorectal cancer cells are able to transfer a 32P radioisotope from the small peptides to cellular proteins; the transfer occurs at a substantially higher rate than in the colorectal cancer cells than in cell lines derived from other cancers or from normal tissues.Type: ApplicationFiled: April 1, 2013Publication date: August 15, 2013Applicant: The Johns Hopkins UniversityInventor: The Johns Hopkins University
-
Publication number: 20130210741Abstract: Peptides for the treatment of inflammation, and therapeutic uses and methods of using the same are disclosed. Peptides including a transducing sequence are effective for inhibiting cytokine activity and TNF-? secretion through interaction with toll-like receptors.Type: ApplicationFiled: January 29, 2013Publication date: August 15, 2013Applicant: 13 THERAPEUTICS, INC.Inventor: 13 Therapeutics, Inc.
-
Publication number: 20130210748Abstract: Method and peptide for regulating cellular activity includes a panel of synthesized peptides that have biological effects on inhibiting or enhancing cellular activity. Selected peptides can be used as therapy to reduce and/or inhibit, or initiate and/or enhance, an inflammatory response in a subject.Type: ApplicationFiled: April 23, 2013Publication date: August 15, 2013Applicants: Oregon Health & Science University, United States of America, as represented by the U.S. Department of Veterans AffairsInventors: United States of America, as represented by the U.S. Department of Veterans Affairs, Oregon Health & Science University
-
Patent number: 8507434Abstract: Compositions and methods that are useful for modulating blood vessel formation, as well as methods that provide for the systematic and efficient identification of angiogenesis modulators are described. As discussed in more detail below, a systematic computational methodology based on bioinformatics was used to identify novel peptide modulators of angiogenesis that have been characterized in vitro and/or in vivo.Type: GrantFiled: January 3, 2008Date of Patent: August 13, 2013Assignee: The Johns Hopkins UniversityInventors: Aleksander S. Popel, Emmanouil D. Karagiannis
-
Patent number: 8507650Abstract: The present invention provides compositions and methods for killing or suppressing growth of Gram-negative bacteria that infect, infest or cause disease in plants, including pathogenic, saprophytic and opportunistic microbes that cause disease in plants and food borne illness in people or in animal feed.Type: GrantFiled: June 4, 2012Date of Patent: August 13, 2013Assignees: Integrated Plant Genetics, Inc., University of Florida Research Foundation, Inc.Inventors: Dean W. Gabriel, Joseph D. Reddy
-
Publication number: 20130203655Abstract: The present invention provides methods to prevent or treat flavivirus infection, and assays for identifying agents which treat flavivirus infection. The present invention also provides compositions for preventing flavivirus infection and a kit for screening an agent that prevents or treats viral infection.Type: ApplicationFiled: February 9, 2011Publication date: August 8, 2013Inventors: Margaret Kielian, Aihua Zheng
-
Publication number: 20130205416Abstract: The present invention provides an agent, in particular a peptide, of formula A, comprising an amino acid sequence X1-X2-X3-X4-X5-X6 (SEQ ID NO 1) wherein X1 can be phenylalanine, isoleucine or tryptophan; X2 can be leucine or phenylalanine or alanine; X3 can be tyrosine or valine; X4 can be leucine, phenylalanine or isoleucine; 10 X5 can be phenyalanine or alanine; and X6 can be valine, arginine or tyrosine, or a fragment or variant of the peptide, wherein said peptide fragment or variant is capable of specifically binding to haemagglutinin, to inhibit the binding of a virus having haemagglutinin on its surface, for use in the treatment of a virus, for example influenza.Type: ApplicationFiled: July 28, 2011Publication date: August 8, 2013Inventors: Anthony Nash, Bernadette Dutia, Mark Stevens
-
Publication number: 20130203649Abstract: TIR-domain decoy peptides and TIR domain peptides are disclosed, as well as methods of using the peptides in the regulation of toll-like receptor (TLR) activation and signaling.Type: ApplicationFiled: February 7, 2013Publication date: August 8, 2013Applicant: UNIVERSITY OF MARYLAND, BALTIMOREInventor: UNIVERSITY OF MARYLAND, BALTIMORE
-
Publication number: 20130203685Abstract: Peptides having the ability to block the activity of acyl-aminoacid releasing enzymes such as AARE or APEH are disclosed. Derivatives of the peptides include oligomers or multimers of the peptide linked to a common scaffold moiety such as a tri-functional amino acid and peptides linked to PEG and fatty acids. Pharmaceutical compositions that include the peptide are also disclosed and can be used to treat various diseases such as cardiovascular diseases, cancer, inflammation, hematological diseases, neurological diseases and urological diseases.Type: ApplicationFiled: February 27, 2013Publication date: August 8, 2013Applicant: CONSIGLIO NAZIONALE DELLE RICERCHEInventor: Consiglio Nazionale delle Ricerche
-
Publication number: 20130203060Abstract: Nucleic acids encoding a new family of small cysteine rich soluble proteins, from a mammal, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.Type: ApplicationFiled: April 1, 2013Publication date: August 8, 2013Applicant: Merck Sharp & Dohme Corp.Inventor: Merck Sharp & Dohme Corp.
-
Patent number: 8501911Abstract: Methods and compounds for decreasing MARCKS-related inflammation and MARCKS-related mucus hypersecretion or decreasing MARCKS-related inflammation in a subject by the administration of a N-terminal myristoylated protein fragment of the N-terminal region of MARCKS protein or a peptide fragment thereof are disclosed.Type: GrantFiled: August 6, 2007Date of Patent: August 6, 2013Assignees: Biomarck Pharmaceuticals, Ltd, North Carolina State UniversityInventors: Yuehua Li, Linda D. Martin, Kenneth B. Adler, Shuji Takashi, Indu Parikh
-
Patent number: 8501907Abstract: The invention relates to antibody compositions and use of the composition to detect disease processes associated with elaboration of proteases. The reagents are directed to assessing an IgG breakdown product that is the result of such proteolytic cleavage. The invention further relates to the use of a therapeutic immunospecific for IgG protease cleavage products to restore effector function to antibody compositions that are subject to protease cleavage.Type: GrantFiled: November 19, 2010Date of Patent: August 6, 2013Assignee: Janssen Biotech, Inc.Inventors: Robert Jordan, David Knight, Randall Brezski, Mary Ryan, Diane Petrone
-
Patent number: 8501905Abstract: The present invention provides synthetic cell platforms. The synthetic cell platforms can be used for culturing cells in vitro. The synthetic cell platforms can also be implanted together with bound cells into an individual. The present invention provides methods of using the platforms to provide cells or progeny of such cells for use in various applications, including clinical applications; and methods of use of the platforms to introduce cells into an individual.Type: GrantFiled: March 21, 2008Date of Patent: August 6, 2013Assignee: The Regents of the University of CaliforniaInventors: David V. Schaffer, Kevin Edward Healy, Lauren Little, Patrick Sean Daugherty
-
Publication number: 20130196899Abstract: The invention provides a synthetic polypeptide of Formula I?: or an amide, an ester or a salt thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia.Type: ApplicationFiled: January 23, 2013Publication date: August 1, 2013Applicant: NOVARTIS AGInventors: Frédéric ZECRI, Andrei GOLOSOV, Philipp GROSCHE, Kayo YASOSHIMA, Hongjuan ZHAO, Qi-Ying HU, Hidetomo IMASE, David Thomas PARKER
-
Publication number: 20130189696Abstract: The invention relates to the discovery that HNA-3a and HNA-3b are antigens within a polypeptide sequence that is highly similar to the CTL2 amino acid sequence.Type: ApplicationFiled: March 18, 2013Publication date: July 25, 2013Applicants: DRK BLUTSPENDEDIENST WEST GMBH, ERNST-MORITZ-ARNDT-UNIVERSITAT GREIFSWALDInventors: Andreas Greinacher, Jan Wesche, Juergen Bux, Angelika Reil
-
Publication number: 20130189784Abstract: Provided are anti-heparan sulfate peptides and methods that employ those peptides for the prevention or treatment of viral infections, including herpesviral infections such as ?-herpesviral, ?-herpesviral, and ?-herpesviral infections, which are exemplified by HSV-1. CMV, and HHV-8 viral infections, respectively. Peptides may comprise at least 10 amino acids of the amino acid sequences XRXRXKXXRXRX (SEQ ID NO: 2), XRXRXXKXRXRX (SEQ ID NO: 8), XXRRRRXRRRXK (SEQ ID NO: 4), and/or KXRRRXRRRRXX (SEQ ID NO: 10), wherein X represents any amino acid. In some embodiments, peptides comprise at least 10 amino acids of the sequence LRSRTKIIRIRH (SEQ ID NO: 1), HRIRIIKTRSRL (SEQ ID NO: 7), MPRRRRIRRRQK (SEQ ID NO: 3), and/or KQRRRIRRRRM (SEQ ID NO: 9). Peptides may be coupled to one or more therapeutic compound(s) to generate peptide-therapeutic compound conjugates, wherein the therapeutic compound may be one or more of a nucleoside analog, an oligosaccharide, and a small molecule.Type: ApplicationFiled: March 15, 2013Publication date: July 25, 2013Applicant: The Board of Trustees of the University of IllinoisInventor: The Board of Trustees of the University of Illinois
-
Publication number: 20130190228Abstract: The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.Type: ApplicationFiled: January 24, 2012Publication date: July 25, 2013Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: Stacey L. Schultz-Cherry, Curtis R. Brandt, Jeremy C. Jones
-
Publication number: 20130190238Abstract: The present invention features peptides, compositions, and related methods for treating gastrointestinal disorders and conditions, including but not limited to, irritable bowel syndrome (IBS), gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia, visceral pain, gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), disorders and conditions associated with constipation, and other conditions and disorders are described herein, using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.Type: ApplicationFiled: February 17, 2011Publication date: July 25, 2013Inventors: Angelika Fretzen, Hong Zhao, Marco Kessler
-
Publication number: 20130190240Abstract: The object of the present invention is to provide an anti-tumor agent having an anti-angiogenic effect and/or an anti-tumor growth effect or a method for tumor growth inhibition. The present invention provides an anti-tumor agent characterized by having an anti-angiogenic effect and/or an anti-tumor growth effect, which contains a polypeptide of galactosylceramide expression factor-1 excluding the Q region, wherein the polypeptide comprises at least the C region or a part thereof.Type: ApplicationFiled: June 24, 2011Publication date: July 25, 2013Inventor: Kiyoshi Ogura
-
Publication number: 20130189711Abstract: The invention involves assays, diagnostics, kits, and assay components for determining levels of K41-glycated CD59 in subjects. Treatments for subjects based upon levels of K41-glycated CD59 also are provided.Type: ApplicationFiled: October 29, 2012Publication date: July 25, 2013Applicant: President and Fellows of Harvard CollegeInventor: President and Fellows of Harvard College
-
Patent number: 8491910Abstract: The present invention relates to compositions for preventing or treating allergy to ragweed by tolerization. The compositions are based on combinations of peptide fragments derived from the major allergen in ragweed pollen, Amb a 1. The invention also relates to products, vectors and formulations which may be used to provide polypeptides of the invention in combination. The invention further relates to in vitro methods for determining whether T cells recognize a polypeptide of the invention, and for determining whether an individual has or is at risk of a condition characterized by allergic symptoms in response to a ragweed allergen.Type: GrantFiled: August 14, 2009Date of Patent: July 23, 2013Assignee: Circassia LimitedInventors: Mark Larche, Roderick Peter Hafner, Paul Laidler
-
Patent number: 8492516Abstract: Disclosed are methods, compositions, zona pellucida binding peptides and polypeptides, and expression vectors for use in species-specific immunocontraception of animals. The disclosed compositions may include immunogenic compositions or vaccines.Type: GrantFiled: March 9, 2012Date of Patent: July 23, 2013Assignee: Auburn UniversityInventors: Tatiana I. Samoylova, Henry J. Baker, Nancy Cox, Stephen Ditchkoff, Kent Van Kampen
-
Publication number: 20130184219Abstract: The invention relates to isolated peptides derived from Oryza sativa Japonica Group, pharmaceutical compositions comprising same, and uses thereof for treating, preventing, ameliorating, and/or delaying the onset of inflammatory and/or neuroinflammatory and/or autoimmune diseases or conditions and in particular multiple sclerosis. The invention further relates to extracts from Oryza sativa Japonica Group and use thereof as a dietary supplement or in a pharmaceutical composition for treating, preventing, ameliorating, and/or delaying the onset of inflammatory, and/or inflammatory, neuroinflammatory and/or autoimmune diseases or conditions. The peptides and the extract of the invention may be used for treating, ameliorating, and/or delaying the onset or preventing multiple sclerosis.Type: ApplicationFiled: June 29, 2010Publication date: July 18, 2013Inventor: Uri Wormser
-
Publication number: 20130183242Abstract: The present invention provides methods for identifying tumor-specific polypeptides, polypeptides so identified, and methods for their use.Type: ApplicationFiled: January 18, 2013Publication date: July 18, 2013Applicant: UNIVERSITY OF CONNECTICUTInventor: UNIVERSITY OF CONNECTICUT
-
Publication number: 20130183237Abstract: The invention relates to thrombin inhibitors derived from the salivary glands of haematophagous arthropods and in particular to bivalent and trivalent thrombin inhibitors that act by interacting with thrombin at two or three different sites.Type: ApplicationFiled: June 18, 2008Publication date: July 18, 2013Applicant: NATIONAL UNIVERSITY OF SINGAPOREInventors: Maria Kazimirova, R. Manjunatha Kini, Cho Yeow Koh
-
Patent number: 8487074Abstract: The present invention relates to the use of an antisecretory protein, derivative, homologue, and/or fragment thereof, having equivalent activity, and/or a pharmaceutically active salt thereof, for the manufacture of a pharmaceutical composition and/or a medical food for the treatment and/or prevention of dysfunction, e.g. abnormal function, hypo- or hyper-function of lipid rafts, receptors and/or caveolae. A dysfunction of lipid rafts, receptors and/or caveolae may be caused by or be a cause of a variety of other conditions, which are also encompassed by the present invention, such as vascular, and lung dysfunctions, and/or endocrine disorders, e.g. diabetes and related disorders. Furthermore, the invention relates to a method for the treatment and/or prevention of dysfunction of lipid rafts and/or caveolae in a mammal in need thereof.Type: GrantFiled: October 27, 2008Date of Patent: July 16, 2013Assignee: Lantmannen AS-Faktor ABInventors: Hans-Arne Hansson, Stefan Lange
-
Publication number: 20130178412Abstract: The invention relates to a S-(2,3-dihydroxypropyl)-cysteine peptide which has two long-chain fatty acids bonded in the form of esters at the dihydroxypropyl group, and which has the following sequence: (SEQ?ID?NO:?1) DhcGN?NDE?SNI?SFK?EK. The invention relates also to a composition comprising the mentioned peptide.Type: ApplicationFiled: September 16, 2008Publication date: July 11, 2013Inventor: Peter F. MUEHLRADT
-
Publication number: 20130177525Abstract: The present invention relates to cyclin D1-derived peptides for use in the improved treatment of cancer in a patient, particularly in the form of a combination therapy using a vaccine. Other aspects relate to the use of the peptides or a combination thereof as a diagnostic tool.Type: ApplicationFiled: June 1, 2011Publication date: July 11, 2013Applicant: IMMATICS BIOTECHNOLOGIES GMBHInventors: Harpreet Singh, Toni Weinschenk, Steffen Walter